Cell­tri­on looks to buy US fa­cil­i­ties to side­step po­ten­tial Trump tar­iffs 

South Ko­re­an bio­phar­ma con­tract man­u­fac­tur­er Cell­tri­on is con­sid­er­ing ac­quir­ing US man­u­fac­tur­ing sites to mit­i­gate Pres­i­dent Don­ald Trump’s po­ten­tial tar­iffs on for­eign-made phar­ma­ceu­ti­cals.

Trump is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER